Applicants should hold a PhD and/or MD, and have postdoctoral research experience in the area of cardiovascular medicine, with specific training in hypertrophic cardiomyopathy (HCM) and variants of the gene MYBPC3. Evidence of scholarly ability (e.g., record of publications in peer-reviewed journals, acquisition of external funding, and presentation experience) is expected.